{"doi":"10.1002/mds.27739","title":"Prediction of Survival With Long‐Term Disease Progression in Most Common Spinocerebellar Ataxia","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Spinocerebellar ataxias are rare dominantly inherited neurodegenerative diseases that lead to severe disability and premature death.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To quantify the impact of disease progression measured by the Scale for the Assessment and Rating of Ataxia on survival, and to identify different profiles of disease progression and survival.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Four hundred sixty‐two spinocerebellar ataxia patients from the EUROSCA prospective cohort study, suffering from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, and spinocerebellar ataxia type 6, and who had at least two measurements of Scale for the Assessment and Rating of Ataxia score, were analyzed. Outcomes were change over time in Scale for the Assessment and Rating of Ataxia score and time to death. Joint model was used to analyze disease progression and survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Disease progression was the strongest predictor for death in all genotypes: An increase of 1 standard deviation in total Scale for the Assessment and Rating of Ataxia score increased the risk of death by 1.28 times (95% confidence interval: 1.18–1.38) for patients with spinocerebellar ataxia type 1; 1.19 times (1.12–1.26) for spinocerebellar ataxia type 2; 1.30 times (1.19–1.42) for spinocerebellar ataxia type 3; and 1.26 times (1.11–1.43) for spinocerebellar ataxia type 6. Three subgroups of disease progression and survival were identified for patients with spinocerebellar ataxia type 1: “severe” (n = 13; 12%), “intermediate” (n = 31; 29%), and “moderate” (n = 62; 58%). Patients in the severe group were more severely affected at baseline with higher Scale for the Assessment and Rating of Ataxia scores and frequency of nonataxia signs compared to those in the other groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Rapid ataxia progression is associated with poor survival of the most common spinocerebellar ataxia. Theses current results have implications for the design of future interventional studies of spinocerebellar ataxia. © 2019 International Parkinson and Movement Disorder Society</jats:p></jats:sec>","journal":"Movement Disorders","year":2019,"id":671812,"datarank":0.4566783656585135,"base_score":3.044522437723423,"endowment":3.044522437723423,"self_citation_contribution":0.4566783656585135,"citation_network_contribution":0.0,"self_endowment_contribution":0.4566783656585135,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":20,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":657257,"name":"Heike Jacobi","orcid":"0000-0002-6986-3969","position":1,"is_corresponding":false},{"id":1755156,"name":"Arron Cook","orcid":"0000-0002-1261-9068","position":2,"is_corresponding":false},{"id":242896,"name":"Paola Giunti","orcid":"0000-0003-3508-4788","position":3,"is_corresponding":false},{"id":1755157,"name":"Michael H. Parkinson","orcid":null,"position":4,"is_corresponding":false},{"id":1599353,"name":"Robyn Labrum","orcid":null,"position":5,"is_corresponding":false},{"id":1420581,"name":"Alexandra Durr","orcid":null,"position":6,"is_corresponding":false},{"id":17405,"name":"Alexis Brice","orcid":"0000-0002-0941-3990","position":7,"is_corresponding":false},{"id":242568,"name":"Perrine Charles","orcid":"0000-0002-3108-2171","position":8,"is_corresponding":false},{"id":1554345,"name":"Cecilia Marelli","orcid":null,"position":9,"is_corresponding":false},{"id":1119214,"name":"Caterina Mariotti","orcid":"0000-0003-2405-3564","position":10,"is_corresponding":false},{"id":1119208,"name":"Lorenzo Nanetti","orcid":"0000-0002-1952-4539","position":11,"is_corresponding":false},{"id":1755158,"name":"Marta Panzeri","orcid":null,"position":12,"is_corresponding":false},{"id":1119213,"name":"Anna Castaldo","orcid":"0000-0003-3459-3521","position":13,"is_corresponding":false},{"id":1755159,"name":"Maria Rakowicz","orcid":null,"position":14,"is_corresponding":false},{"id":1755160,"name":"Rafal Rola","orcid":null,"position":15,"is_corresponding":false},{"id":1755161,"name":"Anna Sulek","orcid":null,"position":16,"is_corresponding":false},{"id":918646,"name":"Tanja Schmitz‐Hübsch","orcid":"0000-0003-4833-5937","position":17,"is_corresponding":false},{"id":1420582,"name":"Ludger Schöls","orcid":null,"position":18,"is_corresponding":false},{"id":657256,"name":"Holger Hengel","orcid":"0000-0002-9773-2667","position":19,"is_corresponding":false},{"id":1755162,"name":"Laszlo Baliko","orcid":null,"position":20,"is_corresponding":false},{"id":1755163,"name":"Bela Melegh","orcid":null,"position":21,"is_corresponding":false},{"id":643485,"name":"Alessandro Filla","orcid":null,"position":22,"is_corresponding":false},{"id":1755164,"name":"Antonella Antenora","orcid":null,"position":23,"is_corresponding":false},{"id":409667,"name":"Jon Infante","orcid":"0000-0003-4025-4606","position":24,"is_corresponding":false},{"id":112862,"name":"José Berciano","orcid":null,"position":25,"is_corresponding":false},{"id":283329,"name":"Bart P. van de Warrenburg","orcid":null,"position":26,"is_corresponding":false},{"id":563611,"name":"Dagmar Timmann","orcid":"0000-0003-1935-416X","position":27,"is_corresponding":false},{"id":651417,"name":"Sylvia Boesch","orcid":"0000-0003-1657-7368","position":28,"is_corresponding":false},{"id":651430,"name":"Wolfgang Nachbauer","orcid":"0000-0001-8292-3690","position":29,"is_corresponding":false},{"id":904281,"name":"Massimo Pandolfo","orcid":"0000-0001-5230-5787","position":30,"is_corresponding":false},{"id":651437,"name":"Jörg B. Schulz","orcid":"0000-0002-8903-0593","position":31,"is_corresponding":false},{"id":316775,"name":"Peter Bauer","orcid":"0000-0003-2811-1354","position":32,"is_corresponding":false},{"id":1755165,"name":"Kang Jun‐Suk","orcid":null,"position":33,"is_corresponding":false},{"id":326382,"name":"Thomas Klockgether","orcid":"0000-0001-6174-5442","position":34,"is_corresponding":false},{"id":867199,"name":"Sophie Tézenas du Montcel","orcid":"0000-0002-2866-4330","position":35,"is_corresponding":false},{"id":1755155,"name":"Alhassane Diallo","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Prediction of Survival With Long‐Term Disease Progression in Most Common Spinocerebellar Ataxia","abstract":"<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Spinocerebellar ataxias are rare dominantly inherited neurodegenerative diseases that lead to severe disability and premature death.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To quantify the impact of disease progression measured by the Scale for the Assessment and Rating of Ataxia on survival, and to identify different profiles of disease progression and survival.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Four hundred sixty‐two spinocerebellar ataxia patients from the EUROSCA prospective cohort study, suffering from spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, and spinocerebellar ataxia type 6, and who had at least two measurements of Scale for the Assessment and Rating of Ataxia score, were analyzed. Outcomes were change over time in Scale for the Assessment and Rating of Ataxia score and time to death. Joint model was used to analyze disease progression and survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Disease progression was the strongest predictor for death in all genotypes: An increase of 1 standard deviation in total Scale for the Assessment and Rating of Ataxia score increased the risk of death by 1.28 times (95% confidence interval: 1.18–1.38) for patients with spinocerebellar ataxia type 1; 1.19 times (1.12–1.26) for spinocerebellar ataxia type 2; 1.30 times (1.19–1.42) for spinocerebellar ataxia type 3; and 1.26 times (1.11–1.43) for spinocerebellar ataxia type 6. Three subgroups of disease progression and survival were identified for patients with spinocerebellar ataxia type 1: “severe” (n = 13; 12%), “intermediate” (n = 31; 29%), and “moderate” (n = 62; 58%). Patients in the severe group were more severely affected at baseline with higher Scale for the Assessment and Rating of Ataxia scores and frequency of nonataxia signs compared to those in the other groups.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Rapid ataxia progression is associated with poor survival of the most common spinocerebellar ataxia. Theses current results have implications for the design of future interventional studies of spinocerebellar ataxia. © 2019 International Parkinson and Movement Disorder Society</jats:p></jats:sec>","is_dataset_classified":null,"base_score":3.044522437723423,"endowment":3.044522437723423,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"31211461","pmcid":null,"openalex_id":"https://openalex.org/W2952159942","authors":[],"funders":[{"funder_name":"Fondation pour la Recherche Médicale","grant_id":"grant number: PLP20151034334","title":null},{"funder_name":"European Commission","grant_id":"305121","title":"Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases"}],"total_grants":2,"fwci":1.6707,"citation_percentile":0.82047235,"influential_citations":0,"citation_trend":[{"year":2020,"count":2},{"year":2021,"count":3},{"year":2022,"count":8},{"year":2023,"count":3},{"year":2024,"count":2},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"bronze","license":"Wiley Online Library User Agreement","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.27739","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.27739","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmds.27739","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.27739","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/mds.27739","host_type":"publisher"},{"url":"https://movementdisorders.onlinelibrary.wiley.com/doi/pdf/10.1002/mds.27739","host_type":"publisher"},{"url":"https://doi.org/10.1002/mds.27739","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/31211461","host_type":"repository"},{"url":"https://hal.sorbonne-universite.fr/hal-03894262","host_type":"repository"},{"url":"http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/290089","host_type":"repository"},{"url":"https://discovery.ucl.ac.uk/id/eprint/10079139/","host_type":"repository"},{"url":"https://pub.dzne.de/search?p=id:%22DZNE-2020-07227%22","host_type":"repository"},{"url":"https://hdl.handle.net/2066/209042","host_type":"repository"},{"url":"http://hdl.handle.net/2066/209042","host_type":"repository"},{"url":"https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/209042","host_type":""},{"url":"https://dx.doi.org/10.1002/mds.27739","host_type":""},{"url":"https://pub.dzne.de/record/140905","host_type":""},{"url":"https://repository.ubn.ru.nl//bitstream/handle/2066/209042/209042.pdf","host_type":""},{"url":"https://dipot.ulb.ac.be/dspace/bitstream/2013/290089/3/Diallo.pdf","host_type":""},{"url":"https://hal.sorbonne-universite.fr/hal-03894262v1","host_type":""},{"url":"https://discovery-pp.ucl.ac.uk/id/eprint/10079139/","host_type":""},{"url":"https://www.ncbi.nlm.nih.gov/pubmed/31211461","host_type":""},{"url":"https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85067496350","host_type":""}],"fields_of_study":["Genetic Neurodegenerative Diseases","Glycogen Storage Diseases and Myoclonus","Amyotrophic Lateral Sclerosis Research","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["Adult","Aged","Deglutition Disorders","Dystonia","Female","Humans","Longitudinal Studies","Male","Middle Aged","Prospective Studies","Time Factors","Cohort Studies","Survival Rate","Machado-Joseph Disease","Disease Progression","Spinocerebellar Ataxias","Cognitive Dysfunction"],"keywords":["Spinocerebellar ataxia","Ataxia","Medicine","Internal medicine","Central nervous system disease","Prospective cohort study","Psychiatry","Longitudinal data","Dynamic Predictions","Eurosca Study","Epoce","Adult","Male","Time Factors","Spinocerebellar Ataxias: mortality","Spinocerebellar Ataxias: physiopathology","Medizin","Dystonia: etiology","Cognitive Dysfunction: physiopathology","Cohort Studies","Neurologie","Humans","Spinocerebellar Ataxias","Cognitive Dysfunction: etiology","Deglutition Disorders: etiology","Cognitive Dysfunction","Longitudinal Studies","Prospective Studies","info:eu-repo/classification/ddc/610","Aged","Spinocerebellar Ataxias: complications","Neurology - Radboud University Medical Center","Radboudumc 3: Disorders of movement DCMN: Donders Center for Medical Neuroscience","Machado-Joseph Disease","Middle Aged","Dystonia: physiopathology","Machado-Joseph Disease: complications","Deglutition Disorders: physiopathology","[SDV] Life Sciences [q-bio]","Survival Rate","Dystonia","Machado-Joseph Disease: physiopathology","Disease Progression","Machado-Joseph Disease: mortality","Female","Deglutition Disorders"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T04:41:25.795086Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}